Yatharth Hospit.

Why is Yatharth Hospital & Trauma Care Services Ltd falling/rising?

As of 24-Jun, Yatharth Hospital & Trauma Care Services Ltd is seeing a slight rise in its stock price to 856.60, driven by strong recent performance, positive investor sentiment, and solid financial fundamentals, including impressive year-to-date growth and consistent positive results over the last 11 quarters. The stock is also trading close to its 52-week high, indicating strong investor confidence.

As of 24-Jun, Yatharth Hospital & Trauma Care Services Ltd is experiencing a slight rise in its stock price, currently at 856.60, with a change of 1.9 (0.22%) upwards. This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has shown strong performance over the past week, gaining 4.29% while the benchmark Sensex has decreased by 0.21%. Additionally, the stock has demonstrated impressive year-to-date growth of 25.68%, significantly outperforming the Sensex, which has declined by 9.66% during the same period. Over the past year, Yatharth Hospital has achieved a remarkable return of 68.34%, contrasting sharply with the Sensex's decline of 6.17%.<BR><BR>Moreover, the stock is currently trading close to its 52-week high, just 4% away from Rs 889.8, indicating strong investor confidence. The stock has also been on a positive trend, gaining for the last three consecutive days with a total return of 1.75% in that period. The moving averages indicate that the stock is trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day averages, further suggesting a bullish trend.<BR><BR>Investor participation is also rising, as evidenced by a delivery volume of 2.45 lacs on June 23, which has increased by 9.97% compared to the 5-day average. This increase in trading activity reflects growing interest in the stock. <BR><BR>Additionally, the company’s strong fundamentals support its rising stock price. It is net-debt free and has reported healthy long-term growth, with net sales increasing at an annual rate of 32.09%. The company has consistently declared positive results for the last 11 consecutive quarters, with net sales reaching a record high of Rs 341.56 crore and a PBDIT of Rs 79.91 crore.<BR><BR>In summary, the combination of strong recent performance, positive investor sentiment, and solid financial fundamentals contributes to the rising stock price of Yatharth Hospital & Trauma Care Services Ltd.

Which are the latest news on Yatharth Hospit.?

What does Yatharth Hospit. do?

Yatharth Hospital & Trauma Care Services Ltd is a small-cap company in the hospital industry, recently reporting net sales of ₹342 Cr and a net profit of ₹48 Cr for March 2026. It was incorporated in 2008 and became a public company in 2021, with a market cap of ₹8,054 Cr.

Overview: <BR>Yatharth Hospital & Trauma Care Services Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated as a Private Limited Company in Delhi on February 28, 2008. It converted its status to a Public Company on November 3, 2021, and changed its name to Yatharth Hospital & Trauma Care Services Limited on November 18, 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 342 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 48 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 8,054 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 46.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 9.89% <BR>Price to Book: 4.55<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Yatharth Hospit.?

As of 10th June, Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 8,054.00 Cr and reported net sales of 1,199.22 Cr and net profit of 176.15 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 8,054.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,199.22 Cr, while the sum of Net Profit for the same period is 176.15 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 1,605.46 Cr, and Total Assets are valued at 1,713.06 Cr.

Who are in the management team of Yatharth Hospit.?

The management team of Yatharth Hospital includes Ajay Kumar Tyagi (Chairman & Wholetime Director), Kapil Kumar (Managing Director), Yatharth Tyagi (Whole-time Director), and independent directors Mukesh Sharma, Sanjeev Upadhyaya, and Promila Bhardwaj, along with Ritesh Mishra as Company Secretary & Compliance Officer.

The management team of Yatharth Hospital includes the following members:<BR><BR>1. **Ajay Kumar Tyagi** - Chairman & Wholetime Director<BR>2. **Kapil Kumar** - Managing Director<BR>3. **Yatharth Tyagi** - Whole-time Director<BR>4. **Mukesh Sharma** - Independent Director<BR>5. **Sanjeev Upadhyaya** - Independent Director<BR>6. **Promila Bhardwaj** - Independent Director<BR>7. **Ritesh Mishra** - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about Yatharth Hospital or its operations, feel free to ask!

Who are the peers of the Yatharth Hospit.?

Yatharth Hospital's peers include Dr Agarwal's Health, Rainbow Children, Health.Global, Jupiter Life Line, Jeena Sikho, Kovai Medical, Artemis Medicare, Indraprastha Medical, and Dr Agarwal's Eye. Yatharth Hospital has a below-average management risk, good growth, excellent capital structure, and the highest 1-year return at 57.94% among its peers.

Peers: The peers of Yatharth Hospit. are Dr Agarwal's Hea, Rainbow Child., Health.Global, Jupiter Life Lin, Jeena Sikho, Kovai Medical, Artemis Medicare, Indrapr.Medical, and Dr Agarwal's Eye.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jupiter Life Lin, Jeena Sikho, and Kovai Medical, while Average management risk is found at Dr Agarwal's Hea, Health.Global, Artemis Medicare, Indrapr.Medical, and Dr Agarwal's Eye, and the rest. Below Average management risk is noted for Yatharth Hospit. In terms of growth, Excellent growth is seen at Health.Global, Jeena Sikho, and Artemis Medicare, while Good growth is observed at Yatharth Hospit., Dr Agarwal's Hea, and the rest, and Below Average growth is found at Rainbow Child. and Jupiter Life Lin. For capital structure, Excellent capital structure is noted at Yatharth Hospit., Jeena Sikho, and Indrapr.Medical, while Good capital structure is found at Dr Agarwal's Hea, Rainbow Child., and Kovai Medical, and the rest.<BR><BR>Return Snapshot: Yatharth Hospit. has the highest 1-year return at 57.94%, while Jeena Sikho has the lowest return, with no percentage available. Compared to its peers, Yatharth Hospit. significantly outperforms them in 1-year returns. Additionally, the peers with negative six-month returns include Dr Agarwal's Hea, Jeena Sikho, Indrapr.Medical, and Dr Agarwal's Eye.

Should I buy, sell or hold Yatharth Hospital & Trauma Care Services Ltd?

Are Yatharth Hospital & Trauma Care Services Ltd latest results good or bad?

Yatharth Hospital & Trauma Care Services Ltd's latest results show strong revenue growth with Q4 FY26 revenues up 47.36% year-on-year, but declining PAT margins to 13.09% raise concerns about sustainability. Overall, the results are mixed, indicating robust growth alongside operational challenges.

Yatharth Hospital & Trauma Care Services Ltd's latest results present a mixed picture. On one hand, the company has shown impressive revenue growth, with Q4 FY26 revenues reaching ₹341.56 crores, marking a 6.58% increase quarter-on-quarter and a remarkable 47.36% increase year-on-year. The net profit for the same quarter was ₹47.52 crores, reflecting a 4.79% rise from the previous quarter and a 22.73% increase year-on-year.<BR><BR>However, there are concerns regarding margin pressures. The PAT margin has declined to 13.09%, down from 16.71% in Q4 FY25, indicating a significant compression of 362 basis points. This decline in profitability metrics raises questions about the sustainability of the company's growth, especially as it continues to expand aggressively.<BR><BR>Overall, while the revenue and profit figures are strong and indicate robust growth, the declining margins suggest that the company is facing operational challenges that investors should monitor closely.

When is the next results date for Yatharth Hospital & Trauma Care Services Ltd?

The next results date for Yatharth Hospital & Trauma Care Services Ltd is 25 May 2026.

The next results date for Yatharth Hospital & Trauma Care Services Ltd is scheduled for 25 May 2026.

How has been the historical performance of Yatharth Hospit.?

Yatharth Hospital has shown significant growth from March 2022 to March 2025, with net sales increasing from 400.94 crore to 880.49 crore, and profit after tax rising from 44.16 crore to 130.55 crore, alongside a substantial improvement in total assets and cash flow. Overall, the hospital has demonstrated robust revenue and profitability growth during this period.

Answer:<BR>The historical performance of Yatharth Hospital shows significant growth in various financial metrics over the past few years.<BR><BR>Breakdown:<BR>Yatharth Hospital's net sales have increased from 400.94 crore in March 2022 to 880.49 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 400.94 crore in March 2022 to 880.49 crore in March 2025. The total expenditure, excluding depreciation, also grew from 290.13 crore in March 2022 to 660.30 crore in March 2025, indicating increased operational costs. Operating profit (PBDIT) has seen a notable increase, climbing from 110.81 crore in March 2022 to 236.37 crore in March 2025. Profit before tax rose from 63.11 crore in March 2022 to 171.74 crore in March 2025, while profit after tax increased from 44.16 crore to 130.55 crore in the same period. The company's total assets have surged from 420.57 crore in March 2022 to 1,713.06 crore in March 2025, with total liabilities also rising from 420.57 crore to 1,713.06 crore. Cash flow from operating activities improved significantly, moving from 59 crore in March 2022 to 149 crore in March 2025, contributing to a net cash inflow of 248 crore in March 2025, up from 6 crore in March 2022. Overall, Yatharth Hospital has demonstrated robust growth in revenue, profitability, and asset base over the past few years.

Is Yatharth Hospit. technically bullish or bearish?

As of November 3, 2025, Yatharth Hospital's technical trend is mildly bullish, supported by a bullish MACD and moving averages, though caution is advised due to a mildly bearish KST and lack of momentum in the RSI.

As of 3 November 2025, the technical trend for Yatharth Hospital has changed from bullish to mildly bullish. The weekly MACD remains bullish, supported by bullish signals from the Bollinger Bands on both weekly and monthly time frames. The daily moving averages also indicate a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The RSI shows no signal on both weekly and monthly charts, indicating a lack of momentum. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from other indicators.

Is Yatharth Hospit. overvalued or undervalued?

As of October 8, 2025, Yatharth Hospital is considered very expensive and overvalued, with a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, despite having a lower PE ratio than peers like Max Healthcare and Fortis Healthcare, while significantly outperforming the Sensex with a year-to-date return of 46.93%.

As of 8 October 2025, the valuation grade for Yatharth Hospital has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, all of which suggest a high valuation relative to earnings and book value.<BR><BR>In comparison to its peers, Yatharth Hospital's PE ratio is lower than that of Max Healthcare at 92.31 and Fortis Healthcare at 86.26, both of which are also categorized as very expensive. However, it is notably higher than Narayana Hrudaya, which has a PE of 46.14 and is classified as expensive. The recent stock performance has outpaced the Sensex, with a year-to-date return of 46.93% compared to the Sensex's 4.65%, reinforcing the notion that the stock is currently overvalued in the market.

Who are the top shareholders of the Yatharth Hospit.?

The top shareholders of Yatharth Hospital include promoter Ajay Kumar Tyagi with 30.59%, mutual funds holding 9.42%, foreign institutional investors at 4.45%, and individual investors with 14.87%. The largest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, with 4.36%.

The top shareholders of Yatharth Hospital include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ajay Kumar Tyagi, with a significant stake of 30.59%. Additionally, mutual funds hold 9.42% of the shares through 8 schemes, while foreign institutional investors (FIIs) account for 4.45% with 30 different FIIs involved. The highest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, which holds 4.36%. Individual investors collectively hold 14.87% of the company's shares.

Has Yatharth Hospit. declared dividend?

No Dividend History Available